Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-348 PK and Safety in Healthy Japanese and Non-Asian Subjects
NCT03250598Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (3 cohorts), sponsored by Agios Pharmaceuticals. Primary endpoints: Area Under the Curve at 72 hours and Maximum Plasma Concentration at 72 hours. Started Aug 2017; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT03250598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250598.